PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Freeline Therapeutics Holdings plc (FRLN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US35655L1070

CUSIP

35655L107

Sector

Healthcare

IPO Date

Aug 7, 2020

Highlights

Market Cap

$28.24M

EPS (TTM)

-$11.40

Target Price

$8.25

Short %

0.61%

Short Ratio

1.92

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
FRLN vs. SPHY
Popular comparisons:
FRLN vs. SPHY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Freeline Therapeutics Holdings plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


FRLN (Freeline Therapeutics Holdings plc)
Benchmark (^GSPC)

Returns By Period


FRLN

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of FRLN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20241.10%1.73%
202323.55%-13.97%-9.90%-24.29%-51.43%2.79%41.09%-4.12%23.21%16.51%25.95%0.95%-10.62%
2022-37.37%-14.52%5.66%-19.63%-14.47%13.00%2.30%-4.55%-17.60%4.29%-12.36%-25.74%-76.01%
2021-1.48%-17.12%-17.51%-10.57%-0.00%-25.91%-41.60%-19.12%-11.43%-12.61%-22.15%-14.66%-89.16%
2020-10.50%-3.10%14.67%-11.17%14.84%1.44%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Freeline Therapeutics Holdings plc (FRLN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
FRLN
^GSPC

There is not enough data available to calculate the Sharpe ratio for Freeline Therapeutics Holdings plc. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
FRLN (Freeline Therapeutics Holdings plc)
Benchmark (^GSPC)

Dividends

Dividend History


Freeline Therapeutics Holdings plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


FRLN (Freeline Therapeutics Holdings plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Freeline Therapeutics Holdings plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Freeline Therapeutics Holdings plc was 99.19%, occurring on Jun 9, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.19%Dec 18, 2020622Jun 9, 2023
-17.55%Nov 5, 20209Nov 17, 202021Dec 17, 202030
-14.74%Aug 21, 202027Sep 29, 202026Nov 4, 202053
-11%Aug 10, 20202Aug 11, 20207Aug 20, 20209

Volatility

Volatility Chart

The current Freeline Therapeutics Holdings plc volatility is 1.46%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


FRLN (Freeline Therapeutics Holdings plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Freeline Therapeutics Holdings plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Freeline Therapeutics Holdings plc.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab